ethyl 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido-[4,3-b]indol-5(2H)-yl)acetate | 1443129-96-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: ethyl 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido-[4,3-b]indol-5(2H)-yl)acetate
• 英文别名: ethyl 2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5-yl)acetate；ethyl 2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetate
• CAS: 1443129-96-1
• 化学式: C₂₆H₂₃FN₂O₃
• 分子量: 430.479
• InChiKey: LFXUOFMPMWKFIO-UHFFFAOYSA-N

物化性质

• 沸点：
  647.6±55.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  51.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido-[4,3-b]indol-5(2H)-yl)acetate 以93的产率得到塞替匹仑
  参考文献：
  名称：

  [EN] TETRAHYDROPYRIDOINDOLE DERIVATIVES
  [FR] DERIVES DE TETRAHYDROPYRIDOINDOLE

  摘要：

  本发明涉及四氢嘧啶吲哚衍生物及其作为制备药物组分的活性成分的使用。本发明还涉及相关方面，包括制备该化合物的过程、包含其中一种或多种该化合物的制药组合物以及通过给予该化合物进行治疗的治疗方法。

  公开号：

  WO2005095397A1
• 作为产物：
  描述：

  8-氟-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚 在 盐酸 、 caesium carbonate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 丙酮 为溶剂， 反应 5.0h， 生成 ethyl 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido-[4,3-b]indol-5(2H)-yl)acetate
  参考文献：
  名称：

  Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist

  摘要：

  Herein we describe the discovery of the novel CRTh2 antagonist 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid 28 (setipiprant/ACT-129968), a clinical development candidate for the treatment of asthma and seasonal allergic rhinitis. A lead optimization program was started based on the discovery of the recently disclosed CRTh2 antagonist 2-(2-benzoyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid 5. An already favorable and druglike profile could be assessed for lead compound 5. Therefore, the lead optimization program mainly focused on the improvement in potency and oral bioavailability. Data of newly synthesized analogs were collected from in vitro pharmacological, physicochemical, in vitro ADME, and in vivo pharmacokinetic studies in the rat and the dog. The data were then analyzed using a traffic light selection tool as a visualization device in order to evaluate and prioritize candidates displaying a balanced overall profile. This data-driven process and the excellent results of the PK study in the rat (F = 44%) and the dog (F = 55%) facilitated the identification of 28 as a potent (IC50 = 6 nM), selective, and orally available CRTh2 antagonist.

  DOI：

  10.1021/jm400122f

文献信息

• J. Med. Chem. 2013, 56, 4899-4911
  作者：

  DOI：——

  日期：——